骨质疏松5种常见联合用药方案

2022-05-31 联合用药 联合用药

骨质疏松症是全身骨骼成分减少的一种现象,就是破骨细胞把骨头吃掉了,主要表现为骨组织内单位体积中骨量减少,由于骨质疏松症病程缓慢而常被忽略,直到发生骨折,被称为寂静的杀手。

骨质疏松信号

看牙齿:原来没有牙病,但牙齿也开始松动了。

看指甲:指甲变软、变脆。

看后背:慢慢出现驼背和身高缩短。

看走路:平衡能力下降,走路不稳,容易摔倒。

总之老年人驼背,易骨折,身高变矮,腰背部疼痛,四肢关节痛,足跟部疼痛以及肢体出现刺痛、麻木感,小心这些骨质疏松初期的表现。

骨质疏松的4大常见问题

1、骨头疼,到底是骨质疏松还是骨关节炎?

骨质疏松症是一种常见的老年退化性疾病,老年人和女性是患骨质疏松症的主要人群,和骨关节炎一样都会表现为骨痛,但骨质疏松引起的疼痛一般是全身骨骼痛,且往往是持续的。

骨关节炎好发于50岁以上人群,女性多于男性,可发生于全身各个关节 ,但更好发于负重较大的膝关节、髋关节、脊柱等,主要表现为关节开始活动时疼痛明显,稍活动后疼痛减轻,而当负重较多或关节活动过多时,疼痛又会加重。

有时,疼痛可呈放射性,骨关节炎患者在发病早期会出现关节僵硬、关节不稳、关节屈伸活动范围减少及步行能力下降等。骨头疼有可能是骨质疏松,还有可能是骨关节炎。

2、糖尿病患者为何更易骨质疏松?

糖尿病随着病程的演变以及患者年龄的增长,胰岛功能的减退可影响骨代谢,加速骨基质的分解,导致钙盐丢失。

由于长期高血糖对肾血管的损害,尿中大量排出微量元素,肾小管对钙、磷、镁等的重吸收减少,影响了骨的重建。

糖尿病患者的新陈代谢容易受到影响,使骨骼胶原蛋白合成不足,骨基质减少。日常生活中的饮食控制也可能导致钙摄入量不足,加重骨质疏松。

3、酒精和烟草对骨质疏松患者的影响?

酒精和烟草中的有害物质及其毒素可致成骨细胞中毒、破坏,使得骨量降低而诱发骨质疏松。

4、骨质疏松患者可选择哪些运动方式?

预防骨质疏松,规律运动很重要,可以选择行走、慢跑、太极拳、瑜伽、舞蹈、乒乓球等运动方式。

联合用药

1、碳酸钙D3片+大豆异黄酮软胶囊

钙的缺乏是导致骨质疏松的关键因素,补钙是解决骨质疏松的有效手段。维生素D助钙更好吸收,摄入钙和维生素D,可以改善骨质密度。

大豆异黄酮可使破骨细胞的活性减弱,成骨细胞的活性加强,有效促进骨质合成,抑制骨质流失,增加骨密度,使骨代谢达到平衡。大豆异黄酮可增加机体对钙的 吸收、利用。两者联用适合于骨质疏松、雌激素分泌过少的人群。

2、阿伦膦酸钠片+维D钙咀嚼片

阿伦膦酸钠主要作用在成熟的破骨细胞,可直接抑制骨吸收增加骨密度。两者联用适合于糖尿病患者伴骨质疏松人群。

3、钙镁加维生素D片+骨松宝颗粒

钙镁同补保证骨壁坚实,增强骨密度,维生素D可以促进身体对于钙质的吸收。骨松宝颗粒补肾活血,强筋壮骨,促进骨形成,抑制骨破坏。两者联用有效预防及改善骨质疏松。

5、碳酸钙D3片+维生素K2软胶囊

两者联用使钙通过肠道吸收,顺利由血钙转化为骨钙,提升钙的吸收沉积率,快速高效的提高骨密度。明显缓解腰酸背痛、脚抽筋及行走乏力等常见的骨质疏松症状。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-08-16 ms7000001894905669

    受益!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-06-03 12192b1am98暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-06-01 Eleven17
  5. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-05-31 ms6000001050879217

    学习收益

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-05-31 xulv123

    认真学习~

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1239165, encodeId=e7c512391651c, content=受益!, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3c68264824, createdName=ms7000001894905669, createdTime=Tue Aug 16 23:58:38 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224188, encodeId=871a12241887d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Fri Jun 03 01:52:07 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514314, encodeId=9ab51514314d6, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592712, encodeId=40961592e1252, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Wed Jun 01 15:12:19 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223561, encodeId=6f4f12235615a, content=学习收益, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6aa8147599, createdName=ms6000001050879217, createdTime=Tue May 31 10:45:38 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223496, encodeId=7fc512234963f, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Tue May 31 06:45:59 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1223495, encodeId=ab3d1223495f2, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Tue May 31 06:40:39 CST 2022, time=2022-05-31, status=1, ipAttribution=)]
    2022-05-31 学医无涯

    学习一下

    0

相关资讯

Mayo Clin Proc:骨质疏松症及其与心血管疾病,呼吸系统疾病和癌症的关系

骨质疏松症影响全球2亿多人,与女性相比,患有骨质疏松症的男性有更高的全因死亡率、包括COPD在内的呼吸系统疾病死亡率和癌症发病率。骨质疏松症与呼吸道疾病和COPD密切相关。

Front Endocrinol (Lausanne):中药仙灵骨葆胶囊可有效且安全地治疗治疗骨质疏松症,改善患者生活质量

骨质疏松症的特点是骨的微结构变形和骨骼脆弱,增加骨折的风险,特别是在绝经后的妇女。仙灵脾胶囊(XLGB)是最值得推荐的用于治疗骨质疏松症的中成药。

Nat Commun:老年人骨质疏松症却容易血管钙化的“钙化矛盾”得到破解

老年人往往有骨质疏松,但是又同时会伴有血管钙化,这种钙的不平衡矛盾,一直难以得到合理解释。甚至产生,老年人该不该补钙的矛盾。以前的观点认为,补钙可能导致血管钙化的发生,对心血管有一定的风险性。但现在的

Cell Prolif:LncRNA-AK137033通过DNA甲基化调控Wnt信号通路,抑制糖尿病骨质疏松症脂肪源性干细胞的成骨潜能

糖尿病(DM)是一种以高血糖为特征的全身性代谢性疾病。这种全身性糖代谢紊乱对骨骼系统产生严重的负面影响,导致骨骼和关节系统的严重并发症,即糖尿病性骨质疏松症(DOP)。

J Bone Miner Res:地诺舒单抗治疗骨质疏松症后用唑来膦酸盐治疗效果研究

在停止使用denosumab(DMAB)的患者中,骨转换迅速增加,在治疗过程中增加的骨量在12到24个月内丢失。因此建议停用DMAB的患者应该接受双膦酸盐的后续治疗,并密切监测。

JGH:长期使用质子泵抑制剂会增加骨质疏松症和髋部骨折的风险

骨质疏松一般指骨质疏松症。 骨质疏松症(osteoporosis)是由于多种原因导致的骨密度和骨质量下降,骨微结构破坏,造成骨脆性增加,从而容易发生骨折的全身性骨病。